| Ytd | -83.70% | |
| 1y | -91.23% |
| Open | 0.91 | Prev Close | 0.96 | Low | 0.78 | High | 1.00 | Mkt Cap | 2.74M |
| Vol | 640.49K | Avg Vol | 602.89K | EPS | -1.96 | P/E | N/A | Forward P/E | -7.46 |
| Beta | 1.45 | Short Ratio | 0.13 | Inst. Own | 0.10% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 1.88 | 200-d Avg | 3.44 | 1yr Est | 9.00 |
KAPA News
Gainers Profound Medical (NASDAQ:PROF) shares moved upwards by 21.5% to $6.9 during Thursday's
Gainers Valneva (NASDAQ:VALN) shares rose 20.6% to $7.09 during Wednesday's after-market sessio
Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) shares increased by 186.0% to $3.58 during Wednesda
Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) stock increased by 59.2% to $1.99 during Wednesday&
Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) shares moved upwards by 64.0% to $2.05 during Tuesd
Kairos Pharma Ltd. (NYSE:KAPA) on Tuesday announced interim efficacy results from its ongoing Phase
Kairos Pharma evaluates ENV-105 with apalutamide in a Phase 2 trial targeting drug-resistant metasta
Gainers Apimeds Pharmaceuticals (AMEX:APUS) shares moved upwards by 52.5% to $7.0 during Tuesday
LOS ANGELES--(BUSINESS WIRE)---- $KAPA--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage